Acadia hits 52-week high on more Phase III PDP data

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) gained $1.54 (23%) to $8.19 on Thursday after presenting additional data from the Phase III ACP-103-020 trial evaluating once-daily oral pimavanserin to treat Parkinson's disease psychosis (PDP). Acadia hit its 52-week high after reporting that pimavanserin met two additional secondary endpoints in the trial -- pimavanserin significantly improved Clinical Global Impression-Severity (CGI-S) scores (p<0.001) and CGI-Improvement (CGI-I) responder analyses vs. placebo (p=0.002). According to the company, the CGI-I responder analyses showed that about twice as many patients in the pimavanserin arm were rated as "very much improved" or "much improved" at the end of the study vs. placebo. The double-blind, North American trial enrolled 199 patients with PDP who received placebo or pimavanserin as an adjunct to stable doses of their existing anti-Parkinson's therapy. Data were presented at the American Academy of Neurology meeting in San Diego.

Acadia had previously reported that pimavanserin met the primary endpoint in the trial of improving antipsychotic efficacy (see BioCentury Extra, Nov. 27, 2012). ...